

Supplementary Table 4. Summary of efficacy outcomes (observed) for patients Continuously treated with ixekizumab for 116 weeks. Data are presented by TNFi-experience and axSpA disease subtype.

	All patients N=352		Biologic DMARD-naïve				TNFi-experienced	
			r-axSpA N=114		nr-axSpA N=104		r-axSpA N=134	
	Week 52	Week 116	Week 52	Week 116	Week 52	Week 116	Week 52	Week 116
Response: n/N (%)								
ASAS20	254/351 (72.4)	260/347 (74.9)	90/114 (78.9)	92/114 (80.7)	80/104 (76.9)	80/103 (77.7)	84/133 (63.2)	88/130 (67.7)
ASAS40	181/351 (51.6)	197/347 (56.8)	67/114 (58.8)	74/114 (64.9)	62/104 (59.6)	60/103 (58.3)	52/133 (39.1)	63/130 (48.5)
ASAS partial remission	69/351 (19.7)	70/347 (20.2)	30/114 (26.3)	31/114 (27.2)	25/104 (24.0)	29/103 (28.2)	14/133 (10.5)	10/130 (7.7)
ASAS 5/6	208/350 (59.4)	210/341 (61.6)	77/114 (67.5)	80/112 (71.4)	67/103 (65.0)	65/102 (63.7)	64/133 (48.1)	65/127 (51.2)
CRP ≤5 mg/L	241/348 (69.3)	260/343 (75.8)	90/114 (78.9)	94/114 (82.5)	79/104 (76.0)	81/103 (78.6)	72/130 (55.4)	85/126 (67.5)
ASDAS LDA (<2.1)	163/347 (47.0)	165/349 (47.3)	67/114 (58.8)	65/114 (57.0)	56/104 (53.8)	55/103 (53.4)	40/129 (31.0)	45/132 (34.1)
ASDAS ID (<1.3)	48/347 (13.8)	53/349 (15.2)	25/114 (21.9)	22/114 (19.3)	15/104 (14.4)	23/103 (22.3)	8/129 (6.2)	8/132 (6.1)
BASDAI50	161/351 (45.9)	174/347 (50.1)	65/114 (57.0)	69/114 (60.5)	51/104 (49.0)	56/103 (54.4)	45/133 (33.8)	49/130 (37.7)
ASDAS clinically important improvement	233/347 (67.1)	247/349 (70.8)	81/114 (71.1)	84/114 (73.7)	74/104 (71.2)	74/103 (71.8)	78/129 (60.5)	89/132 (67.4)
ASDAS major improvement	122/347 (35.2)	130/349 (37.2)	45/114 (39.5)	48/114 (42.1)	37/104 (35.6)	41/103 (39.8)	40/129 (31.0)	41/132 (31.1)
Change from baseline: mean (SD; n)								
ASDAS	-1.63 (1.04; 347)	-1.71 (1.09; 343)	-1.76 (0.98; 114)	-1.82 (0.99; 114)	-1.71 (1.06; 104)	-1.79 (1.20; 103)	-1.44 (1.05; 129)	-1.56 (1.07; 126)
BASDAI	-3.25 (2.18; 351)	-3.40 (2.21; 347)	-3.56 (2.21; 114)	-3.66 (2.18; 114)	-3.52 (2.07; 104)	-3.71 (2.30; 103)	-2.78 (2.16; 133)	-2.93 (2.10; 130)
BASDAI inflammation ^a	-3.54 (2.45; 351)	-3.65 (2.40; 347)	-3.79 (2.47; 114)	-3.84 (2.38; 114)	-3.79 (2.51; 104)	-3.87 (2.53; 103)	-3.12 (2.34; 133)	-3.32 (2.28; 130)
CRP (mg/L)	-10.49 (21.61; 348)	-11.27 (22.40; 343)	-9.70 (13.45; 114)	-9.96 (13.36; 114)	-8.70 (16.33; 104)	-8.91 (16.45; 103)	-12.61 (29.62; 130)	-14.38 (31.21; 126)
PatGA	-3.3 (2.5; 351)	-3.4 (2.6; 347)	-3.5 (2.4; 114)	-3.6 (2.5; 114)	-3.6 (2.4; 104)	-3.7 (2.8; 103)	-3.0 (2.6; 133)	-3.0 (2.5; 130)
BASFI	-2.86 (2.34; 351)	-2.99 (2.36; 347)	-3.06 (2.19; 114)	-3.23 (2.18; 114)	-3.15 (2.60; 104)	-3.28 (2.63; 103)	-2.46 (2.22; 133)	-2.54 (2.23; 130)
BASMI	-0.55 (0.93; 351)	-0.60 (0.97; 345)	-0.61 (0.86; 114)	-0.67 (0.90; 114)	-0.59 (0.95; 104)	-0.57 (0.91; 103)	-0.46 (0.97; 133)	-0.56 (1.07; 128)
ASAS HI	-3.19 (3.43; 351)	-3.37 (3.84; 347)	-3.20 (3.15; 114)	-3.42 (3.69; 114)	-3.77 (3.68; 104)	-3.91 (3.97; 103)	-2.72 (3.42; 133)	-2.91 (3.84; 130)
SF-36 PCS	8.98 (8.03; 351)	9.27 (8.60; 347)	8.89 (7.15; 114)	9.13 (7.63; 114)	10.36 (9.08; 104)	10.58 (10.75; 103)	7.96 (7.78; 133)	8.36 (7.34; 130)
SF-36 MCS	4.41 (9.67; 351)	3.87 (10.45; 347)	4.02 (9.49; 114)	3.35 (9.93; 114)	4.77 (9.44; 104)	4.07 (10.62; 103)	4.47 (10.05; 133)	4.16 (10.81; 130)

Spinal pain due to AS	-3.5 (2.5; 351)	-3.7 (2.5; 347)	-4.0 (2.3; 114)	-4.1 (2.4; 114)	-3.6 (2.6; 104)	-3.8 (2.7; 103)	-3.0 (2.6; 133)	-3.2 (2.4; 130)
Spinal pain at night due to AS	-3.7 (2.6; 351)	-3.8 (2.6; 347)	-4.0 (2.4; 114)	-4.3 (2.5; 114)	-3.9 (2.7; 104)	-4.0 (2.7; 103)	-3.2 (2.7; 133)	-3.2 (2.5; 130)

Baseline was defined as week 0 of originating study.

^aMean of BASDAI questions 5 and 6

Abbreviations: ASAS, Assessment of Spondyloarthritis International Society; ASASx, x% improvement of ASAS criteria; ASAS HI, Assessment of Spondyloarthritis International Society Health Index, ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; ID, inactive disease; IXE, ixekizumab; nr-axSpA, non-radiographic axSpA; PatGA, Patient Global Assessment of Disease Activity; LDA, low disease activity; MCS, Mental Component Score; PCS, Physical Component Score; r-axSpA, radiographic axSpA; SF-36, 36-item Questionnaire Short-Form Health Survey; TNFi, tumour necrosis factor inhibitor; Q2W, every 2 weeks; Q4W, every 4 weeks.